Zim Laboratories Ltd (BSE: 541400) is a Nagpur, Maharashtra-based company in the Medicinal Chemicals and Botanical Products industry. With a market capitalisation of ₹755 Cr, it ranks #1,751 by market cap among the 6,197 Indian listed companies on FinBizNet, and #51 of 86 in Medicinal Chemicals and Botanical Products. At ₹139.55 (as of 16 Nov 2026), the share price is 12.7% below its 52-week high of ₹159.81 and 135.3% above its 52-week low of ₹59.31. The share price is up 98.4% over one year and up 28.4% over three months.
| Current Price | ₹139.55 |
|---|---|
| Market Cap | ₹755 Cr |
| BSE Code | 541400 |
| Sector | Health Care > Pharmaceuticals, Biotechnology and Life Sciences > Pharmaceuticals |
| Sub-Industry | Biotechnology and Life Sciences > Medicinal Chemicals and Botanical Products |
| P/E Ratio | 119.3 |
| Return on Equity | 2.13% |
| Return on Assets | 1.27% |
| 52-Week Range | ₹59.31 – ₹159.81 |
| 1-Year Price Change | +98.4% |
| 3-Month Price Change | +28.4% |
| Beta (1Y) | 0.81 |
| Dividend Yield | 0.00% |
| Headquarters | Nagpur, Maharashtra |
| Website | www.zimlab.in |
| Revenue | ₹105 Cr |
|---|---|
| Net Profit | ₹-2 Cr |
| Net Margin | -1.9% |
| EPS (Basic) | ₹-0.38 |
| Basis | consolidated |
Figures in ₹ crore, parsed from the company's exchange filing (XBRL).
Zim Laboratories Ltd reported revenue of ₹105 Cr in Q2 FY27, up 18.9% from ₹89 Cr in Q2 FY26 and up 12.0% from ₹94 Cr in Q1 FY27. It posted a net loss of ₹2 Cr for the quarter, against a net loss of ₹0 Cr in Q2 FY26. Across the 7 quarters from Q4 FY25 to Q2 FY27, quarterly revenue ranged from ₹72 Cr (Q1 FY26) to ₹109 Cr (Q4 FY25). The company reported a net loss in 4 of these 7 quarters.
| Quarter | Revenue | Net Profit | Net Margin |
|---|---|---|---|
| Q2 FY27 | ₹105 Cr | −₹2 Cr | −1.9% |
| Q1 FY27 | ₹94 Cr | −₹4 Cr | −4.3% |
| Q4 FY26 | ₹105 Cr | ₹4 Cr | 3.6% |
| Q3 FY26 | ₹109 Cr | ₹4 Cr | 4.0% |
| Q2 FY26 | ₹89 Cr | −₹0 Cr | −0.5% |
| Q1 FY26 | ₹72 Cr | −₹2 Cr | −2.6% |
| Q4 FY25 | ₹109 Cr | ₹5 Cr | 4.5% |
Consolidated figures (₹ crore, XBRL filings).
Promoters held 30.30% of Zim Laboratories Ltd's shares as of Sept 2026, against 33.26% in Sept 2025 (−2.96 percentage points). Delivery averaged 48.9% of traded volume across 16 NSE sessions (22 Oct 2026 – 13 Nov 2026).
ZIM Laboratories Limited engages in the development, manufacture, and supply of generic pharmaceutical and nutraceutical products in India and internationally. It provides its products in pre- formulation intermediates and finished formulations in the oral solid dosage forms, such as pellets, taste-masked powders, granules, tablets, capsules, dry syrup, and oral thin films. The company offers therapeutics in the areas of urology, gastroenterology, antibiotics, anti-infectives, cardiovascular, central nervous system, NSAIDs/pain analgesics, and vitamins and supplements. The company was incorporated in 1984 and is based in Nagpur, India.
1. Pharmaceuticals-This segment manufactures, markets, and sells formulation drugs and pre formulation ingredients.
1. Pharmaceuticals-100%
| Company | Market Cap | P/E | ROE | Latest Qtr Revenue | 1Y Change |
|---|---|---|---|---|---|
| Sun Pharmaceutical Industries Limited | ₹4,56,425 Cr | 39.5 | 14.72% | ₹16,199 Cr | +11.2% |
| Laurus Labs Ltd | ₹1,31,242 Cr | 145.6 | 17.74% | ₹2,206 Cr | +146.8% |
| Zydus Lifesciences Ltd | ₹1,19,651 Cr | 24.1 | 18.32% | ₹7,910 Cr | +26.0% |
| Dr.Reddys Lab | ₹1,15,464 Cr | 26.9 | 11.52% | ₹8,698 Cr | +14.5% |
| Cipla Limited | ₹1,14,712 Cr | 29.3 | 11.74% | ₹7,404 Cr | -7.6% |
| Mankind Pharma | ₹1,09,870 Cr | 57 | 12.45% | ₹4,338 Cr | +16.7% |
| Aurobindo Pharma Ltd. | ₹1,05,150 Cr | 30 | 9.93% | ₹10,263 Cr | +59.8% |
| Lupin Ltd | ₹92,087 Cr | 17.3 | 26.91% | ₹7,827 Cr | +0.4% |
| Zim Laboratories Ltd | ₹755 Cr | 119.3 | 2.13% | ₹105 Cr | +98.4% |
Listed by market capitalisation. Ratios are shown for context only.
Zim Laboratories Ltd is trading at ₹139.55, with a market capitalisation of ₹755 Cr.
Zim Laboratories Ltd operates in the Health Care > Pharmaceuticals, Biotechnology and Life Sciences > Pharmaceuticals space (Biotechnology and Life Sciences > Medicinal Chemicals and Botanical Products).
Zim Laboratories Ltd has a P/E of 119.3 and a return on equity of 2.13%.
Zim Laboratories Ltd is listed on the BSE under the scrip code 541400.
Zim Laboratories Ltd's share price is up 98.4% over one year and up 28.4% over three months. Its 52-week range is ₹59.31 to ₹159.81.
In Q2 FY27, Zim Laboratories Ltd reported revenue of ₹105 Cr and net profit of ₹-2 Cr, with basic EPS of ₹-0.38 (consolidated, parsed from the company's exchange filing).
Zim Laboratories Ltd reported revenue of ₹105 Cr in Q2 FY27, up 18.9% from ₹89 Cr in Q2 FY26 and up 12.0% from ₹94 Cr in Q1 FY27.
Promoters held 30.30% of Zim Laboratories Ltd's shares as of Sept 2026, against 33.26% in Sept 2025 (−2.96 percentage points).
Data as of 16 Nov 2026. Descriptive market data only — not investment advice.